InnoCore Pharmaceuticals’ Post

Come hear me and Emily Heffernan, PE talk about “Design Considerations for Multi-Modal Facilities” at the PDA Southeast Chapter next week!

Thoughts on this? >> Pathios rakes in $25M to help start trials for GPR65 inhibitor >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #pharmaceutical #pharma #productmarketing #healthcare

Thoughts on this? >> Pathios rakes in $25M to help start trials for GPR65 inhibitor >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #productmarketing #biotech #pharmaceutical #healthcare #pharma

⚠ News alert Belite Bio, Inc, a subsidiary of Lin Bioscience, today announced that it has entered into a securities purchase agreement with an institutional investor, for the purchase and sale of up to an aggregate of 651,380 American Depositary Shares of the Company (“ADSs”), each ADS representing one ordinary share of the Company at a purchase price of $38.38 per ADS, and the warrants to purchase up to an aggregate of 651,380 ADSs, which will have an initial exercise price equal to $44.14 per ADS and will be immediately exercisable and expire on the five-year anniversary of the issuance, in a registered direct offering. The closing of the offering is expected to occur on or about April 30, 2024, subject to the satisfaction of customary closing conditions. 📖 Read more at: 👉 Belite Bio News Release: https://lnkd.in/gFY8vZi3 #linbioscience #lbs008 #belitebio

The biggest cancer biomed meeting of the year, #ASCO2024 started yesterday. Of the ~6,000 presentations, our biopharmIQ team identified 77 clinical readouts from biopharma companies. Plus, we created a powerful free tool for identifying target abstracts, authors, and their organization. Check out this post for more info. Interesting how many more of the cancer clin readouts are for solid tumors vs. blood cancers (7 of 77 are for blood cancers). Of course, great progress has been made on treating many of the blood cancers. Maybe there aren't as many blood cancer clinical readouts at ASCO because most of those presentations occur at the ASH meeting in December?

We are only 3 days away from DIA 2024! Visit the Vivpro Corp team at booth #1231 for engaging discussions and enjoy freshly made warm churros! Are you attending? Leave us a comment! ⬇ We would love to connect. 😁 #Vivpro #RIA #DIA2024 #MorePowerToYou #BioTech #Pharma #RegulatoryStrategy #RegulatoryAffairs #ClinPharm #AiinPharma

Insights from Day Three of the BIO International Convention in San Diego: https://ow.ly/IrAp50SkhrX. Included in this installment of Scrip’s daily notebook of noteworthy intelligence from the BIO International Convention: • Amgen CEO Bob Bradway taking aim at the "Innovation Reduction Act" • Novo Nordisk's business development head discussing spending its semaglutide bounty • Roivant Sciences's long view on BD prospects for Immunovant's FcRn inhibitor • More regulatory concerns around artificial intelligence #ArtificialIntelligence #InnovationReductionAct #Pharma #Biotech #BIOInternationalConvention

Find targets for typically ‘difficult to drug’ binding pockets, by using Spark’s ‘Macrocyclization’ experiments within your drug discovery projects. Macrocyclic compounds can present several advantages such as: ✨ Diverse functionality ✨ Favorable drug-like properties ✨ Increased selectivity Find out how to drug difficult binding pockets using ligand macrocyclization: https://lnkd.in/ekGTKmjG #DMTA #drugdiscovery #drugdesign #computationalchemistry #compchem #medicinalchemistry #medchem #CADD #cheminformatics

Thoughts on this? >> BridgeBio touts additional ATTR-CM drug data in new analyses of Phase 3 trial >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #pharmaceutical #productmarketing #biotech #healthcare